Precision BioSciences/$DTIL
1D1W1MYTD1Y5YMAX
Capital at risk
About Precision BioSciences
Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).
- Ticker
- $DTIL
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 67
- Headquarters
- Durham, United States
- Website
- precisionbiosciences.com
DTIL Metrics
BasicAdvanced
$175M
-
-$2.59
1.24
-
Price and volume
Market cap
$175M
Beta
1.24
52-week high
$9.62
52-week low
$3.53
Average daily volume
275K
Financial strength
Current ratio
12.822
Quick ratio
12.262
Long term debt to equity
0.585
Total debt to equity
0.62
Interest coverage (TTM)
-27.55%
Profitability
EBITDA (TTM)
-35.148
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-117.04%
Operating margin (TTM)
-80.78%
Revenue per employee (TTM)
$670,000
Management effectiveness
Return on assets (TTM)
-19.37%
Return on equity (TTM)
-135.15%
Valuation
Price to revenue (TTM)
2.861
Price to book
3.69
Price to tangible book (TTM)
3.79
Price to free cash flow (TTM)
-2.461
Free cash flow yield (TTM)
-40.64%
Free cash flow per share (TTM)
-2.573
Growth
Revenue change (TTM)
3,472.96%
Earnings per share change (TTM)
-70.51%
3-year revenue growth (CAGR)
-1.07%
3-year earnings per share growth (CAGR)
-52.36%
What the Analysts think about DTIL
Analyst ratings (Buy, Hold, Sell) for Precision BioSciences stock.
Analyst projections of the future price of Precision BioSciences stock.
DTIL Financial Performance
Revenues and expenses
DTIL Earnings Performance
Company profitability
Upcoming events
No upcoming events
DTIL News
AllArticlesVideos
Precision BioSciences Commences Dosing in Phase 1/2 FUNCTION-DMD Study
Business Wire1 month ago
Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update
Business Wire2 months ago
Precision BioSciences to Report Second Quarter 2026 Financial Results on August 6, 2026
Business Wire2 months ago
Funds containing DTIL
Fund name | Fund size | $DTIL weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.00% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.